Drug Profile
Rigosertib - Onconova Therapeutics
Alternative Names: Estybon; Novonex; ON-01910; ON-01910-sodium; ON-01910.Na; ON-01910Na; Rigosertib sodium; SyB C-1101; SyB L-1101Latest Information Update: 16 Oct 2023
Price :
$50
*
At a glance
- Originator Onconova Therapeutics
- Developer Icahn School of Medicine at Mount Sinai; M. D. Anderson Cancer Center; National Cancer Institute (USA); Onconova Therapeutics; SymBio Pharmaceuticals; Thomas Jefferson University
- Class Amino acids; Antineoplastics; Antivirals; Small molecules; Sulfones
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Microtubule protein inhibitors; Polo-like kinase 1 inhibitors; Ras signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Phase II Acute myeloid leukaemia; Malignant melanoma; Myelofibrosis; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Phase I/II Adenocarcinoma
- Preclinical COVID 2019 infections; Renal cell carcinoma
- No development reported Chronic lymphocytic leukaemia; Head and neck cancer; Ovarian cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 13 Oct 2023 Safety and efficacy data from a phase I/II trial in squamous cell carcinoma (SCC) released by Onconova Therapeutics
- 10 Aug 2023 Onconova Therapeutics plans a registrational trial for RDEB-associated squamous cell carcinoma in USA and provide updates in H1 2024
- 15 May 2023 Onconova request type-B meeting to US FDA for review phase-II trial data for Squamous cell cancer